Biogen BIIB Reportable Segment — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Biogen’s 10-K, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's reportable segment — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's reportable segment — SG&A?
- Biogen (BIIB) reported reportable segment — SG&A of $608.4M in Q4 2025.
- How has Biogen's reportable segment — SG&A changed year-over-year?
- Biogen's reportable segment — SG&A increased by 1.2% year-over-year, from $600.93M to $608.4M.
- What is the long-term trend for Biogen's reportable segment — SG&A?
- Over 3 years (2022 to 2025), Biogen's reportable segment — SG&A has grown at a 0.4% compound annual growth rate (CAGR), from $2.4B to $2.43B.
- What does reportable segment — SG&A mean?
- This encompasses the costs of marketing, sales force operations, legal, and general corporate overhead required to support the segment's commercial activities. It reflects the efficiency of the company's commercial infrastructure and its ability to scale sales without disproportionate cost increases. High levels relative to revenue may indicate aggressive market expansion or high administrative overhead.